Pàgina inicial > Resultats de la cerca: O'Brien, Susan M.
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Dipòsit Digital de Documents de la UAB 2 registres trobats  La cerca s'ha fet en 0.01 segons. 
1.
14 p, 1.1 MB Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia / Kipps, Thomas J. (UC San Diego Moores Cancer Center) ; Fraser, Graeme (McMaster University (Canadà)) ; Coutre, Steven E (Stanford University School of Medicine) ; Brown, Jennifer R. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ; Barrientos, Jacqueline C. (Northwell Health Cancer Institute) ; Barr, Paul M. (University of Rochester) ; Byrd, John C. (The Ohio State University Comprehensive Cancer Center) ; O'Brien, Susan M. (University of California) ; Dilhuydy, Marie-Sarah (Hôpital Haut-Lévêque) ; Hillmen, Peter (University of Leeds) ; Jaeger, Ulrich (Medical University of Vienna) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Cramer, Paula (University of Cologne) ; Stilgenbauer, Stephan (University of Ulm) ; Chanan-Khan, Asher A. (Mayo Clinic Cancer Center) ; Mahler, Michelle (Janssen Research and Development) ; Salman, Mariya (Janssen Research and Development) ; Eckert, Karl (Pharmacyclics LLC. an AbbVie Company) ; Solman, Isabelle G. (Pharmacyclics LLC. an AbbVie Company) ; Balasubramanian, Sriram (Janssen Research and Development) ; Cheng, Mei (Pharmacyclics LLC. an AbbVie Company) ; Londhe, Anil (Janssen Research and Development) ; Ninomoto, Joi (Pharmacyclics LLC. an AbbVie Company) ; Howes, Angela (Janssen Research and Development) ; James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ; Hallek, Michael (University of Cologne) ; Universitat Autònoma de Barcelona
Certain genomic features, such as del(11q), expression of unmutated immunoglobulin heavy-chain variable region (IGHV) gene, or complex karyotype, predict poorer outcomes to chemotherapy in patients with chronic lymphocytic leukemia (CLL). [...]
2019 - 10.1016/j.clml.2019.07.004
Clinical Lymphoma, Myeloma & Leukemia, Vol. 19 Núm. 11 (november 2019) , p. 715-722.e6  
Registre complet - Creative Commons
2.
7 p, 267.3 KB Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations : a pooled analysis from four clinical trials / Allan, John N. (Weill Cornell Medicine) ; Shanafelt, Tait (Stanford University Medical Center) ; Wiestner, Adrian (National Heart, Lung, and Blood Institute) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; O'Brien, Susan M. (University of California Irvine) ; Li, Jianling (Pharmacyclics LLC) ; Krigsfeld, Gabriel (Pharmacyclics LLC) ; Dean, James P. (Pharmacyclics LLC) ; Ahn, Inhye E. (National Heart, Lung, and Blood Institute) ; Universitat Autònoma de Barcelona
TP53 aberrations [del(17p) or TP53 mutation] predict poor survival with chemoimmunotherapy in patients with chronic lymphocytic leukaemia (CLL). We evaluated long-term efficacy and safety of first-line ibrutinib-based therapy in patients with CLL bearing TP53 aberrations in a pooled analysis across four studies: PCYC-1122e, RESONATE-2 (PCYC-1115/16), iLLUMINATE (PCYC-1130) and ECOG-ACRIN E1912. [...]
2021 - 10.1111/bjh.17984
British Journal of Haematology, Vol. 196 (december 2021) , p. 947-953  
Registre complet - Creative Commons

Vegeu també: autors amb noms similars
1 O'Brien, S
2 O'Brien, S.
1 O'Brien, S. M.
1 O'Brien, S.J.
4 O'Brien, Sharon
5 O'Brien, Stephen J.
5 O'Brien, Susan
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem